Cargando…

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting

BACKGROUND: Muscle wasting, a prominent feature of cancer cachexia, is mainly caused by sustained protein hypercatabolism. The enhanced muscle protein degradation rates rely on the activity of different proteolytic systems, although the Adenosine triphosphate (ATP)‐ubiquitin‐proteasome‐dependent pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Penna, Fabio, Bonetto, Andrea, Aversa, Zaira, Minero, Valerio Giacomo, Rossi Fanelli, Filippo, Costelli, Paola, Muscaritoli, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864285/ https://www.ncbi.nlm.nih.gov/pubmed/27239411 http://dx.doi.org/10.1002/jcsm.12050

Ejemplares similares

Cancer-induced muscle wasting: latest findings in prevention and treatment
por: Aversa, Zaira, et al.
Publicado: (2017)

Interference with Ca(2+)-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia
por: Pin, Fabrizio, et al.
Publicado: (2017)

Autophagy is induced in the skeletal muscle of cachectic cancer patients
por: Aversa, Zaira, et al.
Publicado: (2016)

Vitamin D and VDR in cancer cachexia and muscle regeneration
por: Camperi, Andrea, et al.
Publicado: (2017)

Modulating Metabolism to Improve Cancer-Induced Muscle Wasting
por: Penna, Fabio, et al.
Publicado: (2018)

Muscle Wasting and Impaired Myogenesis in Tumor Bearing Mice Are Prevented by ERK Inhibition
por: Penna, Fabio, et al.
Publicado: (2010)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Role of Inflammation in Muscle Homeostasis and Myogenesis
por: Costamagna, Domiziana, et al.
Publicado: (2015)

Liquid Biopsy for Cancer Cachexia: Focus on Muscle-Derived microRNAs
por: Belli, Roberta, et al.
Publicado: (2021)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
por: Accardi, Fabrizio, et al.
Publicado: (2015)

Mitochondrial Dysfunction in Cancer Cachexia: Impact on Muscle Health and Regeneration
por: Beltrà, Marc, et al.
Publicado: (2021)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The Role for Dietary Omega-3 Fatty Acids Supplementation in Older Adults
por: Molfino, Alessio, et al.
Publicado: (2014)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

Control of Skeletal Muscle Atrophy Associated to Cancer or Corticosteroids by Ceramide Kinase
por: Pierucci, Federica, et al.
Publicado: (2021)

Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting
por: Nevi, Lorenzo, et al.
Publicado: (2023)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

Interleukin‐4 administration improves muscle function, adult myogenesis, and lifespan of colon carcinoma‐bearing mice
por: Costamagna, Domiziana, et al.
Publicado: (2020)

The Skeletal Muscle as an Active Player Against Cancer Cachexia
por: Penna, Fabio, et al.
Publicado: (2019)

Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL(3)B
por: Reynolds, Jennifer M, et al.
Publicado: (2007)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
por: Sridhar, Settu, et al.
Publicado: (2013)

The Protective Effects of the Proteasome Inhibitor Bortezomib (Velcade) on Ischemia-Reperfusion Injury in the Rat Retina
por: Chen, Fang-Ting, et al.
Publicado: (2013)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
por: Taromi, Sanaz, et al.
Publicado: (2017)

In situ Electrochemical Evaluation of the Interaction of dsDNA with the Proteasome Inhibitor Anticancer Drug Bortezomib
por: Bunea, Mihaela-Cristina, et al.
Publicado: (2023)

PPARβ/δ Regulates Glucocorticoid- and Sepsis-Induced FOXO1 Activation and Muscle Wasting
por: Castillero, Estibaliz, et al.
Publicado: (2013)

Bortezomib, a Proteasome Inhibitor, Attenuates Angiotensin II-Induced Hypertension and Aortic Remodeling in Rats
por: Li, Shuai, et al.
Publicado: (2013)

The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1
por: Zeniya, Moko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bakm2v2l504gtfrar9ignjcpsf